-- Genentech medicines to be featured in more
than 275 abstracts during ASCO 2015 --
-- New pivotal results for two medicines,
investigational ALK inhibitor alectinib in advanced non-small cell
lung cancer (NSCLC) and Gazyva® (obinutuzumab) in indolent
non-Hodgkin's lymphoma (NHL) --
-- Important data in advanced NSCLC for
investigational cancer immunotherapy, MPDL3280A (anti-PDL1) --
-- Additional results for investigational
medicine cobimetinib in advanced BRAF-mutated melanoma, as well as
Perjeta® (pertuzumab) for the neoadjuvant (pre-surgery) treatment
of people with HER2-positive early breast cancer --
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX:
RHHBY), today announced that data from 10 of its approved cancer
medicines and 10 investigational medicines will be presented during
the American Society of Clinical Oncology (ASCO) Annual Meeting
from May 29 - June 2 in Chicago. These data demonstrate the
strength of Genentech’s oncology pipeline, particularly in cancer
immunotherapy and personalized medicine.
“We’re particularly excited about our data in different types of
advanced lung cancer, including pivotal data for alectinib and
results of the first randomized study of our investigational
immunotherapy, MPDL3280A,” said Sandra Horning, M.D., chief medical
officer and head of Global Product Development. “These results
build upon our long-standing commitment to improve outcomes for
people with lung cancer, and we hope these data will help us bring
new options to treat this devastating disease.”
Updated results from studies of cobimetinib in combination with
Zelboraf® (vemurafenib) will also be presented at ASCO. Cobimetinib
is currently under review with both the U.S. Food and Drug
Administration (FDA) and the European Medicines Agency. Data
presented at ASCO for alectinib and Gazyva will support regulatory
submissions, and the Gazyva data will be highlighted as part of
ASCO's official press program. Genentech is also discussing interim
data for MPDL3280A from the POPLAR study with the FDA as part of
its Breakthrough Therapy Designation in lung cancer.
Preliminary data will also be presented on investigational
medicine venetoclax in NHL and multiple myeloma. The FDA recently
granted Breakthrough Therapy Designation to venetoclax for people
with relapsed/refractory chronic lymphocytic leukemia who have a
genetic abnormality known as 17p deletion.
Visit http://www.gene.com/asco for resources and perspectives
from scientists, doctors and others in the cancer community on
important topics at ASCO this year. Follow Genentech on Twitter via
@Genentech.
Overview of key presentations featuring Genentech medicines
at ASCO 2015
Medicine Abstract title Abstract
number Alectinib (investigational)
Efficacy and safety of the ALK inhibitor
alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who
have failed prior crizotinib: An open-label, single-arm, global
phase II study (NP28673)
#8008 (oral)
Sunday May 31
8:00 AM CDT
A phase II, open-label, multicenter study
of the ALK inhibitor alectinib in an ALK+ non-small-cell lung
cancer (NSCLC) U.S./Canadian population who had progressed on
crizotinib (NP28761)
#8019 (poster discussion)
Monday June 1
8:00 AM CDT
Cobimetinib (investigational)
Update of progression-free survival (PFS)
and correlative biomarker analysis from coBRIM: Phase III study of
cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated
melanoma
#9006 (oral)
Saturday May 30
1:15 PM CDT
Extended follow-up results of phase Ib
study (BRIM7) of vemurafenib (vem) with cobimetinib (cobi) in
BRAF-mutant melanoma
#9020
Monday June 1
1:15 PM CDT
Gazyva (obinutuzumab; investigational
use)
GADOLIN: Primary results from a phase III
study of obinutuzumab plus bendamustine compared with bendamustine
alone in patients with rituximab-refractory indolent non-Hodgkin’s
lymphoma
**To be featured in an official ASCO
Press Briefing on Saturday, May 30, 8:00 – 9:00 AM (CDT)
#LBA8502 (oral)
Monday June 1
9:45 AM CDT
MPDL3280A (anti-PDL1; investigational)
Efficacy, safety and predictive biomarker
results from a randomized phase II study comparing MPDL3280A vs
docetaxel in 2L/3L NSCLC (POPLAR)
#8010 (oral)
Sunday May 31
4:30 PM CDT
Safety and efficacy of MPDL3280A
(anti-PDL1) in combination with platinum-based doublet chemotherapy
in patients with advanced non-small cell lung cancer (NSCLC)
#8030
Monday June 1
8:00 AM CDT
A phase Ia study of MPDL3280A (anti-PDL1):
Updated response and survival data in urothelial bladder cancer
(UBC)
#4501 (oral)
Monday June 1
9:45 AM CDT
Perjeta (pertuzumab)
Five-year analysis of the phase II
NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D)
and/or trastuzumab (T) and/or pertuzumab (P)
#505 (oral)
Monday June 1
8:00 AM CDT
Venetoclax (investigational)
Interim results from a dose-escalation
study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus
bendamustine (B) and rituximab (R) in patients (pts) with
relapsed/refractory (R/R) Non-Hodgkin’s Lymphoma (NHL).
#8535 (poster discussion)
Sunday May 31
8:00 AM CDT
Phase I interim safety and efficacy of
venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory
(R/R) multiple myeloma (MM).
#8576 (poster discussion)
Sunday May 31
8:00 AM CDT
Phase 1b interim results: Venetoclax
(ABT-199/GDC-0199) in combination with bortezomib (BTZ) and
dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma
(MM).
#8580 (poster discussion)
Sunday May 31
8:00 AM CDT
About Genentech in Cancer Immunotherapy
For more than 30 years, Roche and Genentech have been developing
medicines with the goal to redefine treatment in oncology. Today,
we’re investing more than ever in our effort to bring innovative
treatment options that help a person’s own immune system fight
cancer. Our personalized cancer immunotherapy research and
development program includes more than 20 investigational
candidates, seven of which are in clinical trials. All studies
include the evaluation of biomarkers to guide our development and
help identify the right treatment approach for each patient.
MPDL3280A (anti-PDL1) is our most advanced cancer immunotherapy,
with 30 active clinical trials. Nine pivotal
trials across certain types of lung, bladder, breast and
kidney cancer are underway with two additional pivotal studies
slated to begin later this year. We have six ongoing Phase III
studies in lung cancer.
About Genentech in Lung Cancer
Lung cancer is a major area of focus and investment for Roche
and Genentech, and we are committed to developing new approaches,
medicines and tests that can help people with this deadly disease.
Our goal is to provide an effective treatment option for every
person diagnosed with lung cancer. We currently have two approved
medicines to treat certain kinds of lung cancer and more than 10
medicines being developed to target the most common genetic drivers
of lung cancer or to boost the immune system to combat the
disease.
About Gazyva
Gazyva is an engineered monoclonal antibody designed to attach
to CD20, a protein found only on B-cells. It attacks targeted cells
both directly and together with the body's immune system. Gazyva is
thought to have an increased ability to induce direct cell death
and induces greater activity in how it recruits the body’s immune
system to attack B-cells (antibody dependent cellular cytotoxicity;
ADCC) when compared to Rituxan® (rituximab). Gazyva was
discovered by Roche Glycart AG, a wholly owned, independent
research unit of Roche. In the United States, Gazyva is part of a
collaboration between Genentech and Biogen Idec.
Gazyva continues to be investigated in a large clinical program,
which includes the head-to-head Phase III GOYA study comparing
Gazyva plus chemotherapy to Rituxan plus chemotherapy in newly
diagnosed (first-line) diffuse large B-cell lymphoma (DLBCL; an
aggressive form of NHL) and the head-to-head Phase III GALLIUM
study comparing Gazyva plus chemotherapy to Rituxan plus
chemotherapy in previously untreated (first-line) indolent
non-Hodgkin’s lymphoma. Additional combination studies are planned
or underway across a range of blood cancers.
Gazyva Indication
Gazyva is a prescription medicine used with the chemotherapy
drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in
adults who have not had previous CLL treatment.
Important Safety Information
Patients must tell their doctor right away about any side
effects they experience. Gazyva can cause side effects that can
become serious or life-threatening, including:
Hepatitis B Virus (HBV): Hepatitis B can cause liver
failure and death. If a patient has had history of hepatitis B
infection, Gazyva could cause it to return. Patients should not
receive Gazyva if they have active hepatitis B liver disease. The
patient’s doctor or healthcare team will need to screen for
hepatitis B before, and monitor the patient for hepatitis during
and after, treatment with Gazyva. Sometimes this will require
treatment for hepatitis B. Symptoms of hepatitis include: worsening
of fatigue and yellow discoloration of skin or eyes.
Progressive Multifocal Leukoencephalopathy (PML): PML is
a rare and serious brain infection caused by a virus. PML can be
fatal. A patient’s weakened immune system could put the patient at
risk. The patient’s doctor will watch for symptoms. Symptoms of PML
include: confusion, difficulty talking or walking, dizziness or
loss of balance, and vision problems.
Additional possible serious side effects of Gazyva:
Patients must tell their doctor right away about any side
effects they experience. Gazyva can cause side effects that may
become severe or life threatening, including:
- Infusion Reactions: These side effects
may occur during or within 24 hours of any Gazyva infusion. Some
infusion reactions can be serious, including, but not limited to,
severe allergic reactions (anaphylaxis), acute life-threatening
breathing problems, or other life-threatening infusion reactions.
If a patient has a reaction, the infusion is either slowed or
stopped until the patient’s symptoms are resolved. Most patients
are able to complete infusions and receive medication again.
However, if the infusion reaction is serious, the infusion of
Gazyva will be permanently stopped. The patient’s healthcare team
will take a few steps to help lessen any side effects the patient
may have to the infusion process. The patient may be given
medicines to take before each Gazyva treatment. Signs of infusion
reactions may include: dizziness, nausea, chills, fever, vomiting,
diarrhea, breathing problems, and chest pain
- Tumor Lysis Syndrome (TLS): Gazyva
works to break down cancer cells quickly. As cancer cells break
apart, their contents are released into the blood. These contents
may cause damage to organs and the heart, and may lead to kidney
failure requiring the need for dialysis treatment. The patient’s
doctor may prescribe medication to help prevent TLS. The patient’s
doctor will also conduct regular blood tests to check for TLS.
Symptoms of TLS may include nausea, vomiting, diarrhea, and
tiredness
- Infections: While a patient is taking
Gazyva, the patient may develop infections. Some of these
infections may be severe. Fatal infections have been reported, so
the patient should be sure to talk to the doctor if the patient
thinks the patient has one. Patients with active infection should
not be treated with Gazyva. Infections may continue even after the
patient stops taking Gazyva. The patient’s doctor may prescribe
medications to help prevent infections. Symptoms of infection
include fever and cough
- Low White Blood Cell Count: When a
patient has an abnormally low count of infection-fighting white
blood cells, it is called neutropenia. While the patient is taking
Gazyva, the patient’s doctor will do blood work to check the
patient’s white blood cell counts. Neutropenia can develop during
or after treatment with Gazyva. It may also last for more than one
month. If a patient’s white blood cell count is low, the patient’s
doctor may prescribe medication to help prevent infections
- Low Platelet Count: Platelets help stop
bleeding or blood loss. Gazyva may reduce the number of platelets
the patient has in the blood. This may affect the clotting process.
While the patient is taking Gazyva, the patient’s doctor will do
blood work to check the patient’s platelet count
Most common side effects of Gazyva
The most common side effects of Gazyva are infusion reactions,
low white blood cell counts, low platelet counts, low red blood
cell counts, fever, cough, nausea, and diarrhea.
Before receiving Gazyva, patients should talk to their doctor
about:
Immunizations: Before receiving Gazyva therapy, the patient
should tell the patient’s healthcare provider if the patient has
recently received or is scheduled to receive a vaccine. Patients
who are treated with Gazyva should not receive live vaccines.
Pregnancy: A patient should tell the doctor if the patient is
pregnant, plans to become pregnant, or is breastfeeding. It is not
known if Gazyva may harm the patient’s unborn baby or pass into the
patient’s breast milk. The patient should use birth control while
using Gazyva and for 12 months after treatment. Mothers who have
been exposed to Gazyva during pregnancy should discuss the safety
and timing of live virus vaccinations for their infants with their
child’s healthcare providers. The patient should speak to the
doctor about discontinuing Gazyva if the patient is
breastfeeding.
Patients must tell their doctor about any side effect that
bothers them or that does not go away.
These are not all of the possible side effects of Gazyva. For
more information, patients should ask their doctor or
pharmacist.
Gazyva is available by prescription only.
Report side effects to the FDA at (800) FDA-1088, or
http://www.fda.gov/medwatch. Report side effects to
Genentech at (888) 835-2555.
Please visit http://www.Gazyva.com for the full Prescribing
Information, including Boxed WARNINGS, for additional Important
Safety Information.
About Rituxan
Rituxan Indications
Rituxan (rituximab) is indicated for the treatment of patients
with:
- Relapsed or refractory, low-grade or
follicular, CD20-positive, B-cell NHL as a single agent
- Previously untreated follicular,
CD20-positive, B-cell NHL in combination with first-line
chemotherapy and, in patients achieving a complete or partial
response to Rituxan in combination with chemotherapy, as
single-agent maintenance therapy
- Non-progressing (including stable
disease), low-grade, CD20-positive, B-cell NHL, as a single agent,
after first-line CVP chemotherapy
- Previously untreated diffuse large
B-cell, CD20-positive NHL in combination with CHOP or other
anthracycline-based chemotherapy regimens
- Previously untreated and previously
treated CD20-positive CLL in combination with fludarabine and
cyclophosphamide (FC)
Rituxan is not recommended for use in patients with severe,
active infections.
Important Safety Information:
Rituxan can cause serious side effects that can lead to
death, including:
- Infusion Reactions: may occur
during or within 24 hours of the infusion. The patient’s
doctor should give the patient medicines before their treatment.
Symptoms can include hives, rash, itching, facial or oral swelling,
sudden cough, shortness of breath, difficulty breathing, weakness,
dizziness, feeling faint, racing heart or chest pain
- Severe Skin and Mouth Reactions:
symptoms can include painful sores, ulcers, or blisters on the
skin, lips or mouth; peeling skin; rash; or pustules
- Hepatitis B Virus (HBV)
Reactivation: may cause serious liver problems including liver
failure and death. If patients have had hepatitis B or are carriers
of HBV, receiving Rituxan could cause the virus to become an active
infection again. Patients should not receive Rituxan if they have
active HBV liver disease. The patient’s doctor will do blood tests
to check for HBV infection prior to treatment and will monitor the
patient during and for several months following their
treatment
- Progressive Multifocal
Leukoencephalopathy (PML): a rare, serious brain infection that
can lead to severe disability and death and for which there is no
known prevention, treatment or cure. Symptoms can include
difficulty thinking, loss of balance, changes in speech or walking,
weakness on one side of the body or blurred or lost vision
What are the additional possible serious side effects of
Rituxan?
Patients must tell their doctor right away about any side
effects they experience. Rituxan can cause serious side effects
that can lead to death, including:
- Tumor Lysis Syndrome (TLS): may cause
kidney failure and the need for dialysis treatment, abnormal heart
rhythm and can lead to death. The patient’s doctor may give the
patient medicines before their treatment to help prevent TLS
- Serious Infections: can happen during
and after treatment and can lead to death. These infections
may be bacterial, fungal or viral. Symptoms can include fever; cold
or flu symptoms; earache or headache; pain during urination; white
patches in the mouth or throat; cuts or scrapes that are red, warm,
swollen or painful
- Heart Problems: symptoms can include
chest pain and irregular heartbeats that may require treatment. The
patient’s doctor may need to stop their treatment
- Kidney Problems: the patient’s doctor
should do blood tests to check how well the patient’s kidneys are
working
- Stomach and Serious Bowel Problems: can
include blockage or tears in the bowel that can lead to death.
Stomach area pain during treatment can be a symptom
- Low Blood Cell Counts: the patient’s
blood cell counts may be monitored during treatment
Most common side effects of Rituxan
The most common side effects of Rituxan are infusion reactions,
chills, infections, body aches, tiredness and low white blood
cells.
Patients must tell their doctor if they are pregnant, plan to
become pregnant or are breastfeeding. It is not known if Rituxan
may harm the patient’s unborn baby or pass into the patient’s
breast milk. Women should use birth control while using Rituxan and
for 12 months after treatment.
Patients must tell their doctor about any side effect that
bothers them or that does not go away.
These are not all of the possible side effects of Rituxan. For
more information, patients should ask their doctor or
pharmacist.
Report side effects to the FDA at (800) FDA-1088 or
http://www.fda.gov/medwatch. Report side effects
to Genentech at (888) 835-2555.
Please see the Rituxan full Prescribing Information, including
Most Serious Side Effects, for additional important safety
information at http://www.Rituxan.com.
About Zelboraf
Zelboraf is a prescription medicine used to treat a type of skin
cancer called melanoma that has spread to other parts of the body
or cannot be removed by surgery, and has a certain type of abnormal
“BRAF” gene. BRAF is mutated in approximately half of melanomas. A
patient’s healthcare provider will perform a test to make sure that
Zelboraf is right for the patient. Zelboraf is not used to treat
melanoma with a normal BRAF gene. It is not known if Zelboraf is
safe and effective in children under 18 years of age.
Zelboraf is now approved in more than 80 countries and has been
used to treat more than 11,000 patients worldwide. Zelboraf was
co-developed under a 2006 license and collaboration agreement
between Roche and Plexxikon, now a member of the Daiichi Sankyo
Group.
Important Safety Information:
Zelboraf can cause serious side effects, including risk of
cancers. Zelboraf may cause a type of skin cancer called
cutaneous squamous cell carcinoma (cuSCC). New melanoma lesions
have occurred in people who take Zelboraf. Zelboraf may also cause
another type of cancer called non-cutaneous squamous cell carcinoma
(SCC). Patients must talk with their healthcare provider about
their risk for these cancers. Patients must check their skin and
tell their doctor about skin changes including a new wart, a sore
or bump that bleeds or does not heal, or a mole that changes size
or color.
A patient’s healthcare provider should also check for cancers
that may not occur on the skin. Patients must tell their healthcare
provider about any new symptoms that they get while taking
Zelboraf.
While taking Zelboraf, patients should avoid sunlight. When they
go outside, patients must wear clothes that protect their skin,
including their head, face, hands, arms and legs. Patients must use
lip balm and a broad-spectrum sunscreen with SPF 30 or higher.
Possible serious side effects of Zelboraf include severe
allergic reactions, severe skin reactions, potentially
life-threatening changes in the electrical activity of the heart
called QT prolongation, liver injury and eye problems. Patients
must tell their doctor if they are pregnant or plan to become
pregnant, as Zelboraf can harm a patient’s unborn baby.
Common side effects of Zelboraf include joint pain, rash, hair
loss, tiredness, sunburn or sun sensitivity, nausea, itching or
warts.
Patients must tell their doctor if they have any side effect
that bothers them or does not go away. These are not all of the
possible side effects of Zelboraf. For more information about side
effects, patients should ask their doctor or pharmacist.
Report side effects to the FDA at (800) FDA-1088 or
http://www.fda.gov/medwatch. Report side effects to
Genentech at (888) 835-2555.
Patients should read the full Prescribing Information and
Medication Guide for additional Important Safety Information at
http://www.zelboraf.com.
About Perjeta
Perjeta is a medicine that targets the HER2 receptor, a protein
found on the outside of many normal cells and in high quantities on
the outside of cancer cells in HER2-positive cancers. Perjeta is
designed specifically to prevent the HER2 receptor from pairing (or
“dimerizing”) with other HER receptors (EGFR/HER1, HER3 and HER4)
on the surface of cells, a process that is believed to play a role
in tumor growth and survival. Binding of Perjeta to HER2 may also
signal the body’s immune system to destroy the cancer cells. The
mechanisms of action of Perjeta and Herceptin are believed to
complement each other, as both bind to the HER2 receptor, but to
different places. The combination of Perjeta and Herceptin is
thought to provide a more comprehensive blockade of HER signaling
pathways, thus preventing tumor cell growth and survival.
Perjeta Indication Statements
Perjeta is approved for use in combination with Herceptin and
docetaxel chemotherapy in people who have HER2-positive breast
cancer that has spread to different parts of the body (metastatic)
and who have not received anti-HER2 therapy or chemotherapy for
metastatic breast cancer.
Perjeta is approved for use prior to surgery in combination with
Herceptin and docetaxel chemotherapy in people with HER2-positive,
locally advanced, inflammatory, or early stage (tumor is greater
than two centimeters in diameter or node positive) breast cancer.
Perjeta should be used as part of a complete treatment regimen for
early stage breast cancer. This use of Perjeta is based on an
improvement in the percentage of people who had no evidence of
cancer in the breast or lymph nodes at the time of surgery.
Currently, no data have shown whether or not treatment with Perjeta
prior to surgery improves survival. The safety of Perjeta as part
of a doxorubicin (chemotherapy)-containing regimen has not been
established. The safety of Perjeta administered for greater than
six cycles for early stage breast cancer has not been
established.
Important Safety Information
Perjeta may cause heart problems, including those without
symptoms (such as reduced heart function) and those with symptoms
(such as congestive heart failure).
- A patient’s doctor may run tests to
monitor the patient’s heart function before and during treatment
with Perjeta.
- Based on test results, the doctor may
decide to hold or discontinue treatment with Perjeta.
Receiving Perjeta during pregnancy can result in the death of
an unborn baby and birth defects.
- Birth control should be used while
receiving Perjeta and for six months after a patient’s last dose of
Perjeta. If a patient is a mother who is breastfeeding, the patient
should talk with her doctor about either stopping breastfeeding or
stopping Perjeta.
- If a patient thinks she may be
pregnant, the patient should contact their healthcare provider
immediately.
- If a patient is exposed to Perjeta
during pregnancy, the patient is encouraged to enroll in the MotHER
Pregnancy Registry by contacting (800) 690-6720.
Perjeta should not be used in patients who are allergic to
pertuzumab or to any of the ingredients in Perjeta.
Other possible serious side effects of Perjeta therapy
include:
- Infusion-related reactions: Perjeta is
a medicine that is delivered into a vein through a needle. This
process can cause reactions known as infusion-related reactions.
The most common infusion-related reactions when receiving Perjeta,
Herceptin and docetaxel chemotherapy were feeling tired, abnormal
or altered taste, allergic reactions, muscle pain and vomiting. The
most common infusion-related reactions when receiving Perjeta alone
were fever, chills, feeling tired, headache, weakness, allergic
reactions and vomiting.
- Severe allergic reactions: Some people
receiving Perjeta may have severe allergic reactions, called
hypersensitivity reactions or anaphylaxis. This reaction may be
severe, may happen quickly and may affect many areas of the
body.
Perjeta has only been shown to work in people with HER2-positive
breast cancer.
The most common side effects of Perjeta when given with
Herceptin and docetaxel chemotherapy for treatment of breast cancer
that has spread to other parts of the body (metastatic) are:
- Diarrhea
- Hair loss
- Low levels of white blood cells with or
without a fever
- Nausea
- Feeling tired
- Rash
- Damage to the nerves (numbness,
tingling, pain in hands/feet)
The most common side effects of Perjeta when given with
Herceptin and docetaxel chemotherapy as part of an early stage
breast cancer regimen before surgery are:
- Hair loss
- Diarrhea
- Nausea
- Low levels of white blood cells with or
without a fever
The most common side effects of Perjeta when given with
Herceptin and docetaxel chemotherapy following three cycles of
epirubicin, cyclophosphamide and fluorouracil as part of an early
stage breast cancer regimen before surgery are:
- Feeling tired
- Hair loss
- Diarrhea
- Nausea
- Vomiting
- Low levels of white blood cells with or
without a fever
The most common side effects of Perjeta when given with
Herceptin, docetaxel chemotherapy and carboplatin chemotherapy as
part of an early stage breast cancer regimen before surgery
are:
- Feeling tired
- Hair loss
- Diarrhea
- Nausea
- Vomiting
- Low levels of white blood cells with or
without a fever
- Low platelet count
- Low levels of red blood cells
Report side effects to Genentech and the FDA. Report side
effects to the FDA at (800) FDA-1088 or
http://www.fda.gov/medwatch. Report side effects to
Genentech at (888) 835-2555.
Please see Perjeta full Prescribing Information including Most
Serious Side Effect for additional Important Safety Information at
http://www.perjeta.com.
About Genentech
Founded more than 35 years ago, Genentech is a leading
biotechnology company that discovers, develops, manufactures and
commercializes medicines to treat patients with serious or
life-threatening medical conditions. The company, a member of the
Roche Group, has headquarters in South San Francisco, California.
For additional information about the company, please visit
http://www.gene.com.
GenentechMedia Contact:Susan Willson, 650-467-6800Advocacy
Contact:Sonali Chopra, 650-467-0842Investor Contacts:Nina Goworek,
650-467-8737Karl Mahler, 011 41 61 687 8503
Rocky Old Man Energy (TSXV:RO)
Historical Stock Chart
From Apr 2024 to May 2024
Rocky Old Man Energy (TSXV:RO)
Historical Stock Chart
From May 2023 to May 2024